Fig. 3From: Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in JapanOne-way sensitivity analysis. PPS: Post-progression survival, PFS: Progression-free survival, ICER: Incremental cost-effectiveness ratio, JPY: Japanease yen, QALY: Quality adjusted life yearsBack to article page